MedTrace Logo

Rivaroxaban in Type 2 Myocardial Infarctions

NCT04838808 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-03-27

No results posted yet for this study

Summary

This trial is the pilot phase of a randomized controlled trial to test the feasibility of recruiting patients with a type 2 myocardial infarction and randomizing them to low-dose rivaroxaban to reduce the risk of major cardiovascular events.

Conditions

  • Type II Myocardial Infarction

Interventions

DRUG

Rivaroxaban 2.5 MG [Xarelto]

Rivaroxaban 2.5mg twice daily for 90-days

DRUG

Placebo

Placebo tablet twice daily for 90-days

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Principal Investigators

  • Michelle Graham, MD · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-05
Primary Completion
2022-05-12
Completion
2023-01-03

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04838808 on ClinicalTrials.gov